Skip to main content
Top
Published in: Diabetology International 1/2013

01-03-2013 | Case report

A patient who developed symptomatic reactive hypoglycemia 14 years after total gastrectomy and was successfully treated with miglitol

Authors: Yasushi Kondo, Kentaro Toyoda, Tomohiro Santo, Junko Fujii, Mitsuo Fukushima, Nobuya Inagaki, Koichiro Yasuda

Published in: Diabetology International | Issue 1/2013

Login to get access

Abstract

We report the case of an 85-year-old man who had undergone total gastrectomy 14 years prior to admission at our hospital. He lost consciousness and was urgently hospitalized. His blood samples showed severe hypoglycemia (plasma glucose level 8 mg/dl) with hyperinsulinemia (immunoreactive insulin level 174.4 μU/ml) on admission. Laboratory data and imaging studies showed there was no insulinoma. He took garenoxacin mesilate hydrate for flu several days before admission. Such severe hypoglycemia did not recur after cessation of garenoxacin, and it was reported that hypoglycemia was induced by garenoxacin, which promoted insulin secretion, which indicated that garenoxacin had the possibility of inducing severe hypoglycemia. After admission, reactive hypoglycemia by dumping syndrome was diagnosed by mixed-meal tolerance test. The patient began developing symptoms after medication with irbesartan (angiotensin receptor blocker) for essential hypertension 1 month before admission. This preceded irbesartan, which is known to increase insulin sensitivity and may cause symptomatic dumping syndrome. Laboratory data also showed the presence of insulin autoimmune syndrome with a high titer of anti-insulin autoantibody. Although the antibody showed a low affinity and a high bound capacity, blood glucose profile during admission only showed the pattern of reactive hypoglycemia. Therefore, insulin autoimmune syndrome was unlikely the cause of hypoglycemic events in this case. The meal tolerance test showed better efficacy of miglitol to inhibit postmeal hyperglycemia and subsequent hyperinsulinemia than did acarbose and voglibose. We speculate that the angiotensin receptor blocker caused symptomatic dumping syndrome, and only miglitol among α-glucosidase inhibitors suppressed the symptom.
Literature
1.
go back to reference Maeda N, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol. 1996;117:372–6.PubMedCrossRef Maeda N, et al. Increase in insulin release from rat pancreatic islets by quinolone antibiotics. Br J Pharmacol. 1996;117:372–6.PubMedCrossRef
2.
go back to reference Henriksen EJ, Jacob S, Kinnick TR, et al. Selective angiotensin II receptor antagonism reduces insulin resistance in Obese Zucker rats. Hypertension. 2001;38:884–90.PubMedCrossRef Henriksen EJ, Jacob S, Kinnick TR, et al. Selective angiotensin II receptor antagonism reduces insulin resistance in Obese Zucker rats. Hypertension. 2001;38:884–90.PubMedCrossRef
3.
go back to reference Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Invest. 1997;100:2158–69.PubMedCrossRef Folli F, Kahn CR, Hansen H, et al. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. J Clin Invest. 1997;100:2158–69.PubMedCrossRef
4.
go back to reference Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59:521–49.PubMedCrossRef Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs. 2000;59:521–49.PubMedCrossRef
5.
go back to reference Kawamori R, Toyota T, Oka Y, et al. Improvement of glycaemic control following 12-week treatment with miglitol in Japanese type 2 diabetics: a double-blind, randomized, placebo-and voglibose-controlled trial. Diabetes Metab. 2003;29:4S263. Kawamori R, Toyota T, Oka Y, et al. Improvement of glycaemic control following 12-week treatment with miglitol in Japanese type 2 diabetics: a double-blind, randomized, placebo-and voglibose-controlled trial. Diabetes Metab. 2003;29:4S263.
6.
go back to reference Hiki M, Shimada K, Daida H, et al. Single administration of α-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease. Circ J. 2010;74:1471–8.PubMedCrossRef Hiki M, Shimada K, Daida H, et al. Single administration of α-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease. Circ J. 2010;74:1471–8.PubMedCrossRef
7.
go back to reference Uchida D, Nakamura S, Tatsuno I, et al. Evaluation of miglitol and voglibose effect on postprandial plasma glucose after test meal A loading. J Japan Diabetes Soc. 2008;51(5):411–8. Uchida D, Nakamura S, Tatsuno I, et al. Evaluation of miglitol and voglibose effect on postprandial plasma glucose after test meal A loading. J Japan Diabetes Soc. 2008;51(5):411–8.
8.
go back to reference Aoki K, Nakamura A, Terauchi Y, et al. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. Diabetes Res Clin Pract. 2007;78:30–3.PubMedCrossRef Aoki K, Nakamura A, Terauchi Y, et al. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. Diabetes Res Clin Pract. 2007;78:30–3.PubMedCrossRef
9.
go back to reference Aoki K, Muraoka T, Terauchi Y, et al. Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. Intern Med. 2010;49:1083–7.CrossRef Aoki K, Muraoka T, Terauchi Y, et al. Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. Intern Med. 2010;49:1083–7.CrossRef
10.
go back to reference Arakawa M, Ebato C, Hirose T, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metab Clin Exp. 2008;57:1299–306.PubMedCrossRef Arakawa M, Ebato C, Hirose T, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metab Clin Exp. 2008;57:1299–306.PubMedCrossRef
11.
go back to reference Imbof A, Scbneemann M, Scbaffner A. Reactive hypoglycaemia due to late dumping syndrome: successful treatment with acarbose. Swiss Med Wkly. 2001;131:81–3. Imbof A, Scbneemann M, Scbaffner A. Reactive hypoglycaemia due to late dumping syndrome: successful treatment with acarbose. Swiss Med Wkly. 2001;131:81–3.
Metadata
Title
A patient who developed symptomatic reactive hypoglycemia 14 years after total gastrectomy and was successfully treated with miglitol
Authors
Yasushi Kondo
Kentaro Toyoda
Tomohiro Santo
Junko Fujii
Mitsuo Fukushima
Nobuya Inagaki
Koichiro Yasuda
Publication date
01-03-2013
Publisher
Springer Japan
Published in
Diabetology International / Issue 1/2013
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-012-0082-y

Other articles of this Issue 1/2013

Diabetology International 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine